Table of Contents
<< Previous Issue | Aug 2014 (Vol: 2014, Issue: 8) | Next Issue >> |
- Section: Licensing
-
Synairgen Partners with AstraZeneca to Advance its Lead Asthma Programme
-
Shire Licenses Hunter Syndrome Therapy from ArmaGen Technologies
- Section: Mergers & Acquisitions
-
Teva Advances Pain Management Strategy with Labrys Biologics Acquisition
-
Merck & Co. Accelerates Development of All-Oral HCV Triple-Drug Regimen with Idenix Acquisition
-
Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit
- Section: Research & Development
-
GSK Highlights Immuno-Oncology Focus with Adaptimmune Collaboration
-
Bayer Returns to Gene Therapy Arena with Dimension Therapeutics Deal
-
Pfizer Makes Significant Entry into CAR-T Field with Cellectis Pact